CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.

In this 15-minute CME activity, two experts provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma.

In an interim look at the SKYSCRAPER-01 study, investigators found tiragolumab plus atezolizumab didn’t meaningfully slow tumor progression compared to atezolizumab alone in patients with advanced, newly diagnosed non-small cell lung cancer (NSCLC). Tiragolumab has now fallen short in two phase 3 lung cancer trials, having already missed its study objectives in advanced SCLC earlier this year.

A phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in patients with unresectable stage III NSCLC and no progression after concurrent chemoradiotherapy. With a median follow-up of 11.5 months, both combinations increased ORR and prolonged PFS versus durvalumab alone. Safety was similar across arms with no new or significant safety signals identified with either combination.

Researchers explain why the Omicron variant of COVID-19 is so contagious and spreads so rapidly in the general population.

As use of gabapentin in the United States has been steadily increasing in recent years, researchers from the CDC have found that, among the 62,652 overdose deaths that occurred between 2019 and 2020, 58,362 of these cases had documented toxicology results.